Home > Clinical Trials

Saved trials

RECRUITING
NCT02390752
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
54 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1)
Neurofibroma, Plexiform


Precursor Cell Lymphoblastic Leukemia-Lymphoma


Leukemia, Promyelocytic, Acute


Sarcoma
RECRUITING
NCT07459673
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
60 Enrollment(s)
7 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer


HER2-positive Breast Cancer


Breast Cancer Stage IV
RECRUITING
NCT06989112
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
600 Enrollment(s)
249 Study location(s)
INTERVENTIONAL (PHASE3)
Endometrial Cancer
RECRUITING
NCT05845450
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
197 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Colorectal Cancer


Resectable Colorectal Carcinoma
TERMINATED
NCT05744375
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
2 Enrollment(s)
19 Study location(s)
INTERVENTIONAL (PHASE2)
Locally Advanced Breast Cancer


Metastatic Breast Cancer
RECRUITING
NCT05417594
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
695 Enrollment(s)
33 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Advanced Solid Malignancies
ACTIVE_NOT_RECRUITING
NCT04618913
Anticoagulation in Patients With Venous Thromboembolism and Cancer
1 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Neoplasms


Embolism
RECRUITING
NCT07069712
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
100 Enrollment(s)
70 Study location(s)
INTERVENTIONAL (PHASE2)
Gastroesophageal Adenocarcinoma